Search hospitals

>

Missouri

>

Saint Louis

Washington University School Of Medicine

Claim this profile

Saint Louis, Missouri 63110

Global Leader in Cancer

Global Leader in Lung Cancer

Conducts research for Breast Cancer

Conducts research for Pancreatic Cancer

Conducts research for Solid Tumors

3130 reported clinical trials

429 medical researchers

Photo of Washington University School Of Medicine in Saint LouisPhoto of Washington University School Of Medicine in Saint LouisPhoto of Washington University School Of Medicine in Saint Louis

Summary

Washington University School Of Medicine is a medical facility located in Saint Louis, Missouri. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Pancreatic Cancer, Solid Tumors and other specialties. Washington University School Of Medicine is involved with conducting 3,130 clinical trials across 2,259 conditions. There are 429 research doctors associated with this hospital, such as Robert J. Hayashi, Brian A Van Tine, M.D., Ph.D., Timothy R Smith, and Douglas R. Adkins.

Area of expertise

1

Cancer

Global Leader

Washington University School Of Medicine has run 320 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage I
2

Lung Cancer

Global Leader

Washington University School Of Medicine has run 229 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
EGFR positive

Top PIs

Clinical Trials running at Washington University School Of Medicine

Lung Cancer

Breast Cancer

Ovarian Cancer

Breast cancer

Colorectal Cancer

Brain Tumor

Testicular cancer

Multiple Myeloma

Cancer

Prostate Cancer

Image of trial facility.

High-Dose Radiation + Chemotherapy and Immunotherapy

for Non-Small Cell Lung Cancer

This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.

Recruiting

2 awards

Phase 3

14 criteria

Image of trial facility.

Radiation Therapy

for Brain Metastasis

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.

Recruiting

2 awards

Phase 3

12 criteria

Image of trial facility.

Treatment Timing

for Non-Small Cell Lung Cancer

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.

Recruiting

2 awards

Phase 3

4 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Washington University School Of Medicine?

Where is Washington University School Of Medicine located?

Who should I call to ask about financial aid or insurance network?

What insurance does Washington University School Of Medicine accept?

What awards or recognition has Washington University School Of Medicine received?